Literature DB >> 7283060

Modern autotransfusion. Experience with a washed red cell processing technique.

W V Sharp, M Stark, D L Donovan.   

Abstract

The technique of intraoperative autotransfusion utilizing the Haemonetics Cell Saver is described. This device separates and washes red blood cells removed from the surgical field. Advantages of this unit over others are (1) no systemic anticoagulation is required, (2) circulatory fibrin debris is removed, (3) plasma hemoglobin is removed, and (4) any circulating anticoagulant is removed. Experience with 136 consecutive cases. 101 elective and 35 emergency, is reported. The only complication was coagulopathy, which occurred in 5.1 percent of the cases. It is easily treated with blood component therapy and occurs in those patients in whom greater then 3,500 cm3 of blood is autotransfused. The Cell Saver has proven an important adjunct in surgical patients in whom greater than 1,000 cm3 of blood will be lost, as well as in emergency patients. It provides an efficient, economical and safe method to autotransfuse blood.

Entities:  

Mesh:

Year:  1981        PMID: 7283060     DOI: 10.1016/0002-9610(81)90390-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Washing and filtering of cell-salvaged blood - does it make autotransfusion safer?

Authors:  Gerhardt Konig; Jonathan H Waters
Journal:  Transfus Altern Transfus Med       Date:  2012-12-01

Review 2.  Intraoperative autotransfusion.

Authors:  J L Glover; T A Broadie
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

3.  The effect of salvaged blood on coagulation function as measured by thromboelastography.

Authors:  Gerhardt Konig; Mark H Yazer; Jonathan H Waters
Journal:  Transfusion       Date:  2012-08-31       Impact factor: 3.157

4.  Intraoperative autotransfusion. Experience in 725 consecutive cases.

Authors:  M M Keeling; L A Gray; M A Brink; V K Hillerich; K I Bland
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.